Bio-Techne (TECH) Income from Non-Controlling Interests (2020 - 2022)
Bio-Techne (TECH) posted quarterly Income from Non-Controlling Interests of -$212000.0 for Q2 2023, down 102.29% year-over-year from $9.3 million in Q2 2022, and down 200.0% quarter-over-quarter from $212000.0 in Q4 2022.
Analysis
Bio-Techne (TECH) Income from Non-Controlling Interests (2020 - 2022) Analysis & Trends
Bio-Techne's Income from Non-Controlling Interests history runs 10 years deep, the most recent figure standing at -$212000.0 for Q2 2023.
- In Q2 2023, Income from Non-Controlling Interests fell 102.29% year-over-year to -$212000.0; the TTM figure through Jun 2023 stood at -$33000.0 (down 100.38% YoY), while the FY2023 annual figure was -$33000.0, up 52.86% from the prior year.
- Income from Non-Controlling Interests for Q2 2023 stood at -$212000.0, down from $212000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $9.3 million in Q2 2022, with the low at -$634000.0 in Q3 2021.
- The 4-year median for Income from Non-Controlling Interests is $32500.0 (2021), against an average of $846300.0.
- The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests jumped 10319.1% in 2022, then plunged 102.29% in 2023.
- Bio-Techne's Income from Non-Controlling Interests stood at $83000.0 in 2020, then fell by 20.48% to $66000.0 in 2021, then jumped by 221.21% to $212000.0 in 2022, then slumped by 200.0% to -$212000.0 in 2023.
- Business Quant data shows TECH's Income from Non-Controlling Interests at -$212000.0 in Q2 2023, $212000.0 in Q4 2022, and -$33000.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | - |
| 10 | Bio-Techne | 11.30 Bn | 11.03 Bn | 211.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 179,000.00 |
| Jun 30, 2022 | 391,000.00 |
| Mar 31, 2022 | -595,000.00 |
| Dec 31, 2021 | -8.11 Mn |
| Sep 30, 2021 | -634,000.00 |
| Jun 30, 2021 | -316,000.00 |
| Mar 31, 2021 | -380,000.00 |
| Dec 31, 2020 | -130,000.00 |